Leflunomide: a novel DMARD for the treatment of rheumatoid arthritis

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.2, Iss.1, 2001-01, pp. : 125-137

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Leflunomide for the treatment of rheumatoid arthritis

By Miceli-Richard Corinne Dougados Maxime

Expert Opinion on Pharmacotherapy, Vol. 4, Iss. 6, 2003-06 ,pp. : 987-997

Informa Healthcare

Access to resources Recommend Favorite

Iguratimod: novel DMARD promising for rheumatoid arthritis

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

JAK inhibition for the treatment of rheumatoid arthritis: a new era in oral DMARD therapy

By Vaddi Kris Luchi Monica

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 7, 2012-07 ,pp. : 961-973

Informa Healthcare

Access to resources Recommend Favorite

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide for Rheumatoid Arthritis in Germany: II. The Contribution of Leflunomide to Efficiency

By Schädlich Peter K.

PharmacoEconomics, Vol. 23, Iss. 4, 2005-01 ,pp. : 395-420

Adis International

Access to resources Recommend Favorite

Modelling Cost Effectiveness and Cost Utility of Sequential DMARD Therapy Including Leflunomide in Rheumatoid Arthritis in Germany: I. Selected DMARDs and Patient-Related Costs

By Schädlich Peter K.

PharmacoEconomics, Vol. 23, Iss. 4, 2005-01 ,pp. : 377-393

Adis International

Access to resources Recommend Favorite